OncoMatch/Colorectal Cancer (CRC)/EGFR
Colorectal Cancer (CRC)EGFR Clinical Trials
EGFR is the target of cetuximab and panitumumab, anti-EGFR monoclonal antibodies approved as standard of care for RAS/BRAF wild-type metastatic CRC. EGFR overexpression by IHC is common in CRC but less predictive than RAS/BRAF mutational status. Trials explore novel anti-EGFR antibodies, bispecific constructs, antibody-drug conjugates targeting EGFR, and strategies to restore sensitivity after acquired EGFR-pathway resistance.
Top recruiting EGFR Colorectal Cancer (CRC) trials
Ranked by phase and US site count. See all 9 trials matched to your profile →
A Study of Bispecific Antibody MCLA-158 in Patients With Advanced Solid Tumors
Merus B.V.
A Phase 2 Study of Zanidatamab in Patients With HER2-expressing Tumors
Jazz Pharmaceuticals
A Study of Amivantamab Monotherapy and in Addition to Standard-of-Care Chemotherapy in Participants With Advanced or Metastatic Colorectal Cancer
Janssen Research & Development, LLC
A Study to Evaluate the Safety and Efficacy of A2B395, an Allogeneic Logic-gated CAR T, in Participants With Solid Tumors That Express EGFR and Have Lost HLA-A*02 Expression
A2 Biotherapeutics Inc.
APL-101 Study of Subjects With NSCLC With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors
Apollomics Inc.
Evaluation of 89Zr-DFO-nimotuzumab for Non-invasive Imaging of EGFR+ Cancers by Positron Emission Tomography (PET)
University of Saskatchewan
Browse other molecular targets with active Colorectal Cancer (CRC) trials.